Genentech's Early Cancer Technology Scout On Partnering, Roche Setup & BD Challenges

There is still much more to be learnt about cancer immunology, particularly what drives cancer cell growth, proliferation and resistance mechanisms, says Kevin Sin, Genentech's VP of oncology business development. Speaking to Scrip at the recent BIO-Europe Spring partnering conference, Sin describes Genentech's partnering strategy in oncology and how, almost a decade after the merger, Roche and Genentech are still working collaboratively and competitively to find the best new science in cancer.

Series of images showing different stages of destruction of a tumor cell. 3D illustration. Can be used to illustrate effect of drugs, medicines, microbes, nanoparticles
Genentech's oncology deals VP outlines his data wishes & valuation methods for early-stage programs

Cancer therapy is changing too rapidly at present for it to make sense to have a strict partnering strategy listing specific areas to invest in, according to Genentech Inc.'s vice president of oncology business development Kevin Sin.

In an exclusive interview during the recent BIO-Europe Spring partnering event in Barcelona, March 20-22, Sin told Scrip that static...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer